1. Home
  2. GFAI vs ALXO Comparison

GFAI vs ALXO Comparison

Compare GFAI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GFAI
  • ALXO
  • Stock Information
  • Founded
  • GFAI 2018
  • ALXO 2015
  • Country
  • GFAI Singapore
  • ALXO United States
  • Employees
  • GFAI N/A
  • ALXO N/A
  • Industry
  • GFAI Diversified Commercial Services
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GFAI Consumer Discretionary
  • ALXO Health Care
  • Exchange
  • GFAI Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • GFAI 23.3M
  • ALXO 24.0M
  • IPO Year
  • GFAI N/A
  • ALXO 2020
  • Fundamental
  • Price
  • GFAI $1.22
  • ALXO $0.48
  • Analyst Decision
  • GFAI Strong Buy
  • ALXO Strong Buy
  • Analyst Count
  • GFAI 1
  • ALXO 6
  • Target Price
  • GFAI $4.50
  • ALXO $3.30
  • AVG Volume (30 Days)
  • GFAI 452.0K
  • ALXO 600.5K
  • Earning Date
  • GFAI 04-28-2025
  • ALXO 08-07-2025
  • Dividend Yield
  • GFAI N/A
  • ALXO N/A
  • EPS Growth
  • GFAI N/A
  • ALXO N/A
  • EPS
  • GFAI N/A
  • ALXO N/A
  • Revenue
  • GFAI $36,347,373.00
  • ALXO N/A
  • Revenue This Year
  • GFAI $5.66
  • ALXO N/A
  • Revenue Next Year
  • GFAI $4.69
  • ALXO N/A
  • P/E Ratio
  • GFAI N/A
  • ALXO N/A
  • Revenue Growth
  • GFAI 0.18
  • ALXO N/A
  • 52 Week Low
  • GFAI $0.76
  • ALXO $0.40
  • 52 Week High
  • GFAI $3.88
  • ALXO $8.78
  • Technical
  • Relative Strength Index (RSI)
  • GFAI 57.19
  • ALXO 50.61
  • Support Level
  • GFAI $1.14
  • ALXO $0.44
  • Resistance Level
  • GFAI $1.24
  • ALXO $0.53
  • Average True Range (ATR)
  • GFAI 0.07
  • ALXO 0.04
  • MACD
  • GFAI 0.00
  • ALXO 0.01
  • Stochastic Oscillator
  • GFAI 78.57
  • ALXO 61.67

About GFAI Guardforce AI Co. Limited

Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: